Re-cloning Monoclonal Cell Lines for Therapeutic Protein Titer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The biopharmaceutical industry faces challenges in reducing the cost of biologics manufacturing to make therapeutic proteins more accessible to patients, primarily due to high costs associated with improving therapeutic protein productivity and ensuring product safety and efficacy through clonality assurance.

Innovation Solution

A method involving the re-cloning of monoclonal cell lines under optimized culture conditions, with selection using a selection agent like methionine sulfoximine (MSX), to increase the titer of recombinant polypeptides, thereby enhancing therapeutic protein production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If re-cloning is performed to improve therapeutic protein productivity, then titer increases, but manufacturing process complexity increases

Engineering Contradiction:

Improvetherapeutic protein productivityVSAvoidmanufacturing process complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent performs re-cloning of monoclonal cell lines before production to pre-select clones with higher titer. This preliminary action ensures that only high-productivity clones proceed to manufacturing, improving therapeutic protein productivity while managing process complexity through structured pre-screening

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the selection agent concentration parameter during re-cloning to optimize clone selection. By adjusting MSX concentration and other cultural parameters, the process identifies clones with superior productivity characteristics, resolving the contradiction between improving productivity and managing process complexity

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If selection agent concentration is increased during re-cloning, then clone selection precision improves, but cell stress increases

Engineering Contradiction:

Improveclone selection precisionVSAvoidcell stress

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial selection pressure by using optimized but not maximal selection agent concentrations during re-cloning. This approach provides sufficient precision for clone selection while avoiding excessive cell stress that would occur with higher concentrations, balancing selection precision with cell health

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The patent employs staged selection where selection agent concentration is adjusted in phases during re-cloning. This periodic adjustment allows progressive selection precision improvement while giving cells time to adapt, reducing cumulative stress while maintaining selection effectiveness

Inventive Principle:

Principle #19Periodic action

Data Source

PatentUS20250115666A1Cell culture methods for producing therapeutic proteins

Publication Date: 2025.04.10 BRISTOL MYERS SQUIBB CO

AI summary

The present invention generally relates to a method of producing a therapeutic protein of interest from host cells through a new re-cloning strategy.